The gastroesophageal cancer market—including gastric cancer, esophageal adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma—is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. The PD-1 inhibitor Opdivo (Bristol Myers Squibb) expanded its label in the United States to esophageal cancer patients and is under regulatory review, along with Keytruda (Merck & Co.), for first-line and resectable gastroesophageal cancer populations. The approval of the HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) has also expanded the treatment options for HER2-positive patients. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.

QUESTIONS ANSWERED

  • How is gastroesophageal cancer segmented between specific subpopulations, and how are these defined? How does the current treatment landscape differ among esophageal cancer, gastric cancer, and GEJ adenocarcinoma patients?
  • What is the expected market impact of recent drug approvals and label expansions, such as Opdivo, Keytruda and Enhertu on the various subpopulations of gastroesophageal cancer?
  • Which are the most promising emerging therapies and how will they shape the future of the gastroesophageal cancer market?
  • What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • August 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Major-Market Share of Drug Classes in Gastroesophageal Cancer: 2019
          • Major-Market Share of Drug Classes in Gastroesophageal Cancer: 2029
          • Major-Market Sales of Key Therapies for Gastroesophageal Cancer: 2019-2029
          • Major-Market Sales for Gastroesophageal Cancer by Population Segment: 2019-2029
          • Drug-Treatable Population Share and Major-Market Sales Share in Gastroesophageal Cancer: 2019
          • Drug-Treatable Population Share and Major-Market Sales Share in Gastroesophageal Cancer: 2029
          • Population Positioning of Therapies in Gastroesophageal Cancer: United States and Europe
          • Population Positioning of Therapies in Gastroesophageal Cancer: Japan
          • Gastroesophageal Cancer SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • COVID19: Expert insights
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Gastroesophageal Cancer?
          • What Factors Are Constraining the Market for Gastroesophageal Cancer?
        • Segment-Specific Trends
          • Patient Share Dynamics of Key Players in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
          • Patient Share Dynamics of Key Players in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in Japan: 2019-2029
          • Patient Share Dynamics of Key Players in Resectable Esophageal Cancer in the United States: 2019-2029
          • Patient-Share Dynamics of Key Players in First-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
          • Patient-Share Dynamics of Key Players in First-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in Japan: 2019-2029
          • Patient Share Dynamics of Key Players in First-Line Metastatic HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
          • First-Line Metastatic Esophageal Cancer
          • Patient-Share Dynamics of Key Players in First-Line Metastatic Esophageal Cancer in the United States: 2019-2029
          • Patient-Share Dynamics of Key Players in Second- and Third-Line Metastatic Esophageal Cancer in the United States: 2019-2029
          • Patient-Share Dynamics of Key Players in Third- and Fourth-Line Metastatic HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma in the United States: 2019-2029
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Disease Pathophysiology
            • Anatomy of the Stomach and the Gastroesophageal Junction
            • Anatomy of the Esophagus
            • Histological Subtypes and Development of Gastric and Gastroesophageal Junction Adenocarcinoma
            • Key Stages in the Development of Intestinal and Diffuse Types of Gastric and Gastroesophageal Junction Adenocarcinoma
            • Histological Subtypes and Development of Esophageal Cancer
          • Staging and Classification
            • AJCC / UICC TNM Classification System for Gastroesophageal Cancer
            • AJCC / UICC Clinical Staging Classification System for Gastroesophageal Cancer
            • AJCC / UICC Pathological Staging Classification System for Gastroesophageal Cancer
            • AJCC / UICC Postneoadjuvant Therapy Staging Classification System for Gastroesophageal Cancer
          • Key Pathways and Drug Targets
            • Drug Targets and Potential Therapies for Gastroesophageal Cancer
            • Drug Targets for Gastroesophageal Cancer
            • Biology of Immune Checkpoint Inhibitors and Modulators
        • Epidemiology
          • Introduction
            • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of Gastroesophageal Cancer
            • Number of Diagnosed Incident Cases of Gastroesophageal Cancer
            • Definition
            • Methods
            • Sources Used for Stage Distribution of Gastroesophageal Cancer
            • Diagnosed Incident Cases of Gastric and GEJ Adenocarcinoma by Stage Distribution
            • Diagnosed Incident Cases of Esophageal Adenocarcinoma by Stage Distribution
            • Diagnosed Incident Cases of Esophageal Squamous Cell Carcinoma by Stage Distribution
            • Definition
            • Methods
            • Sources Used for Recurrent Incidence of Gastroesophageal Cancer
            • Recurrent Incident Cases of Gastroesophageal Cancer
            • Definition
            • Methods
            • Sources
            • Molecular Subtype
            • Gastric and Gastroesophageal Junction Adenocarcinoma Patient Flow
            • Drug-Treatable Cases of Gastric and Gastroesophageal Junction Adenocarcinoma: 2019-2029
            • Esophageal Adenocarcinoma Patient Flow
            • Drug-Treatable Cases of Esophageal Adenocarcinoma: 2019-2029
            • Esophageal Squamous Cell Carcinoma Patient Flow
            • Drug-Treatable Cases of Esophageal Squamous Cell Carcinoma: 2019-2029
            • Drug-Treated Populations
            • Drug-Treated Cases of Gastroesophageal Cancer: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Gastroesophageal Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Gastroesophageal Cancer
              • Current Treatments Used for Gastroesophageal Cancer
              • Market Events Impacting the Use of Key Current Therapies for Gastroesophageal Cancer
              • Key Results from Select Clinical Trials Investigating Cyramza for the Treatment of Gastroesophageal Cancer
              • Ongoing Clinical Development of Cyramza
              • Key Ongoing Clinical Trials of Cyramza in the Treatment of Gastroesophageal Cancer
              • Expert Insight: Cyramza
              • Key Results from Select Clinical Trials Investigating Herceptin for the Treatment of Gastroesophageal Cancer
              • Ongoing Clinical Development of Herceptin
              • Expert Insight: Herceptin
              • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Gastroesophageal Cancer
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of Gastroesophageal Cancer
              • Expert Insight: Keytruda
              • Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Gastroesophageal Cancer
              • Ongoing Clinical Development of Opdivo
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of Gastroesophageal Cancer
              • Expert Insight: Opdivo
              • Lonsurf
              • Key Results from Select Clinical Trials Investigating Lonsurf for the Treatment of Gastroesophageal Cancer
              • Ongoing Clinical Development of Lonsurf
              • Expert Insights: Lonsurf
            • Medical Practice
              • Localized and Resectable Locally Advanced Gastroesophageal Cancer
              • Unresectable Locally Advanced Gastroesophageal Cancer
              • First-Line Metastatic Gastroesophageal Cancer
              • Second-Line Gastroesophageal Cancer
              • Third- and Fourth-Line Metastatic Gastroesophageal Cancer
              • Patient Characteristics Influencing Drug Selection in Gastroesophageal Cancer
              • Region-Specific Treatment Practices
              • Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: United States
              • Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: United States
              • Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Europe
              • Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: Europe
              • Treatment Decision Tree for Locally Advanced and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Japan
              • Treatment Decision Tree for Locally Advanced and Metastatic Esophageal Cancer: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Gastroesophageal Cancer
            • Top Unmet Needs in Gastroesophageal Cancer: Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for Gastroesophageal Cancer
                • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Bavencio
                • Expert Insight: Bavencio
                • Expectations for Market Authorization and Sales Opportunity of Bavencio in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Tislelizumab for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Tislelizumab in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Tislelizumab
                • Expert Insight: Tislelizumab
                • Expectations for Market Authorization and Sales Opportunity of Tislelizumab in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Imfinzi
                • Expectations for Market Authorization and Sales Opportunity of Imfinzi in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Tecentriq
                • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Tiragolumab
                • Expectations for Market Authorization and Sales Opportunity of Tiragolumab in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Tyvyt for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Tyvyt in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Tyvyt
                • Expectations for Market Authorization and Sales Opportunity of Tyvyt in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Enhertu for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Enhertu in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Enhertu
                • Expert Insight: Enhertu
                • Expectations for Market Authorization and Sales Opportunity of Enhertu in Gastroesophageal Cancer
                • Margetuximab
                • Key Results from Select Clinical Trials Investigating Margetuximab for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Margetuximab in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for margetuximab
                • Expert Insight: Margetuximab
                • Expectations for Market Authorization and Sales Opportunity of Margetuximab in Gastroesophageal Cancer
                • Tukysa
                • Key Ongoing Clinical Trials of Tukysa in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Tukysa
                • Expectations for Market Authorization and Sales Opportunity of Tukysa in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Rivoceranib for the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Rivoceranib
                • Expert Insight: Rivoceranib
                • Expectations for Market Authorization and Sales Opportunity of Rivoceranib in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Stivarga for the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Stivarga
                • Expert Insight: Stivarga
                • Expectations for Market Authorization and Sales Opportunity of Stivarga in Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Pamiparib in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Pamiparib
                • Expert Insight: Pamiparib
                • Expectations for Market Authorization and Sales Opportunity of Pamiparib in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating TAS-118 for the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for TAS-118
                • Expert Insight: TAS-118
                • Expectations for Market Authorization and Sales Opportunity of TAS-118 in Gastroesophageal Cancer
                • Key Results from Select Clinical Trials Investigating Zolbetuximab for the Treatment of Gastroesophageal Cancer
                • Key Ongoing Clinical Trials of Zolbetuximab in the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Zolbetuximab
                • Expert Insight: Zolbetuximab
                • Expectations for Market Authorization and Sales Opportunity of Zolbetuximab in Gastroesophageal Cancer
                • Bemarituzumab
                • Key Results from Select Clinical Trials Investigating Bemarituzumab for the Treatment of Gastroesophageal Cancer
                • Analysis of Clinical Development Program for Bemarituzumab 
                • Expert Insight: Bemarituzumab
                • Expectations for Market Authorization and Sales Opportunity of Bemarituzumab in Gastroesophageal Cancer
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for Gastroesophageal Cancer
            • Access and Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Access Considerations in Gastroesophageal Cancer: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Gastroesophageal Cancer: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Gastroesophageal Cancer: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Gastroesophageal Cancer Bibliography

          Author(s): Fiona Wiegert; Monica Rana

          Fiona Wiegert, M.Sc., is a business insights analyst on the Oncology team at Clarivate. She has a background in market research and analysis within the pharmaceutical industry and experience in several oncology indications. Previously, she worked on product-specific business cases and forecast models at Accord Healthcare. She earned a master’s degree in cognitive neuroscience from the University of Sussex and was awarded the prize for best performance on this course.


          Related Reports

          Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Esophageal Cancer | Disease Landscape & Forecast | G7 | 2020

          The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain limi...

          View Details

          Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

          In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

          View Details